INKT Stock Summary and Trading Ideas (Mink Therapeutics | NASDAQ:INKT)

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Mink Therapeutics trades on the NASDAQ stock market under the symbol INKT.

As of March 4, 2025, INKT stock price declined to $8.10 with 14,580 million shares trading.

INKT has a beta of -0.42, meaning it tends to be less sensitive to market movements. INKT has a correlation of 0.00 to the broad based SPY ETF.

INKT has a market cap of $32.10 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, INKT traded as high as $13.79 and as low as $.46.

The top ETF exchange traded funds that INKT belongs to (by Net Assets): VTI, VXF, IWC.

INKT has outperformed the market in the last year with a return of +752.6%, while the SPY ETF gained +13.9%. In the last 3 month period, INKT beat the market returning +1025.0%, while SPY returned -4.2%. However, in the most recent 2 weeks INKT has underperformed the stock market by returning -14.7%, while SPY returned -5.4%.

INKT support price is $8.00 and resistance is $9.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INKT shares will trade within this expected range on the day.